Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents

被引:14
作者
Zhanel, GG
Karlowsky, JA
Zelenitsky, SA
Turik, MA
Hoban, DJ
机构
[1] Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB R3A 1R9, Canada
[2] Hlth Sci Ctr, Dept Med, Winnipeg, MB R3A 1R9, Canada
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada
[4] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada
[5] Lilly Res Labs, Indianapolis, IN USA
关键词
D O I
10.1128/AAC.42.9.2446
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fifty-two percent of stool specimens collected from 1,200 high-risk patients were colonized with yeasts, primarily Candida albicans (53.6%) and Candida glabrata (35.7%). Susceptibilities to all antifungal agents tested, including LY303366, were similar to those reported previously for Candida species isolated from blood.
引用
收藏
页码:2446 / 2448
页数:3
相关论文
共 8 条
[1]  
EDWARDS Jr JE, 1995, PRINCIPLES PRACTICE, P2289
[2]   Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. [J].
Ernst, ME ;
Klepser, ME ;
Wolfe, EJ ;
Pfaller, MA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 26 (3-4) :125-131
[3]   Candidemia in a Canadian tertiary care hospital from 1976 to 1996 [J].
Karlowsky, JA ;
Zhanel, GG ;
Klym, KA ;
Hoban, DJ ;
Kabani, AM .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (01) :5-9
[4]   MECHANISMS OF ASSOCIATION OF CANDIDA-ALBICANS WITH INTESTINAL-MUCOSA [J].
KENNEDY, MJ ;
VOLZ, PA ;
EDWARDS, CA ;
YANCEY, RJ .
JOURNAL OF MEDICAL MICROBIOLOGY, 1987, 24 (04) :333-341
[5]  
Merz William G., 1995, P709
[6]  
*NAT COMM CLIN LAB, 1995, REF METH BROTH DIL A
[7]   In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents [J].
Pfaller, MA ;
Messer, SA ;
Coffman, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :763-766
[8]   In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species [J].
Zhanel, GG ;
Karlowsky, JA ;
Harding, GAJ ;
Balko, TV ;
Zelenitsky, SA ;
Friesen, M ;
Kabani, A ;
Turik, M ;
Hoban, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :863-865